Thiotepa information

Thiotepa
Clinical data
Trade names	Tepadina
AHFS/Drugs.com	Monograph
MedlinePlus	a682821
License data	US DailyMed: Thiotepa;
Pregnancy; category	AU: D; ;
Routes of; administration	Intravenous, intracavitary, intravesical
ATC code	L01AC01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Pharmacokinetic data
Metabolism	Liver (CYP2B6, CYP3A)
Elimination half-life	1.5–4.1 hours
Excretion	Kidney; 6 hours for thiotepa; 8 hours for TEPA
Identifiers
	IUPAC name 1,1′,1′′-Phosphorothioyltriaziridine;
CAS Number	52-24-4 ;
PubChem CID	5453;
IUPHAR/BPS	7622;
DrugBank	DB04572 ;
ChemSpider	5254 ;
UNII	905Z5W3GKH;
KEGG	D00583 ;
ChEMBL	ChEMBL671 ;
CompTox Dashboard (EPA)	DTXSID0021339 ;
ECHA InfoCard	100.000.124
Chemical and physical data
Formula	C6H12N3PS
Molar mass	189.22 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES S=P(N1CC1)(N2CC2)N3CC3;
	InChI InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2 ; Key:FOCVUCIESVLUNU-UHFFFAOYSA-N ;
	(what is this?) (verify)

Thiotepa (INN^[6]), sold under the brand name Tepadina, is a medication used to treat cancer.^[4]^[5]^[7]

Thiotepa is an organophosphorus compound with the formula (C₂H₄N)₃PS.^[8] It is an analog of N,N′,N″-triethylenephosphoramide (TEPA), which contains tetrahedral phosphorus and is structurally akin to phosphate. It is manufactured by heating aziridine with thiophosphoryl chloride.^{[citation needed]}

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^ "Tepadina (Link Medical Products Pty Ltd T/A Link Pharmaceuticals)". Therapeutic Goods Administration (TGA). 28 September 2022. Archived from the original on 18 March 2023. Retrieved 29 April 2023.
^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^ ^a ^b "Tepadina- thiotepa injection, powder, for solution". DailyMed. Archived from the original on 12 August 2021. Retrieved 11 August 2021.
^ ^a ^b "Tepadina EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 March 2021. Retrieved 30 April 2021.
^ "International Non-Proprietary Names for Pharmaceutical Preparations. Recommended International Non-Proprietary Names (Rec. I.N.N.): List 4" (PDF). World Health Organization. March 1962. p. 111. Archived (PDF) from the original on 18 May 2016. Retrieved 27 November 2016.
^ Cite error: The named reference FDA was invoked but never defined (see the help page).
^ Maanen MJ, Smeets CJ, Beijnen JH (August 2000). "Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA)". Cancer Treatment Reviews. 26 (4): 257–68. doi:10.1053/ctrv.2000.0170. PMID 10913381.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

[2] "Tepadina (Link Medical Products Pty Ltd T/A Link Pharmaceuticals)". Therapeutic Goods Administration (TGA). 28 September 2022. Archived from the original on 18 March 2023. Retrieved 29 April 2023.

[3] "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.

[Tepadina_FDA_label-4] "Tepadina- thiotepa injection, powder, for solution". DailyMed. Archived from the original on 12 August 2021. Retrieved 11 August 2021.

[Tepadina_EPAR-5] "Tepadina EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 March 2021. Retrieved 30 April 2021.

[INN-6] "International Non-Proprietary Names for Pharmaceutical Preparations. Recommended International Non-Proprietary Names (Rec. I.N.N.): List 4" (PDF). World Health Organization. March 1962. p. 111. Archived (PDF) from the original on 18 May 2016. Retrieved 27 November 2016.

[FDA-7] Cite error: The named reference FDA was invoked but never defined (see the help page).

[8] Maanen MJ, Smeets CJ, Beijnen JH (August 2000). "Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA)". Cancer Treatment Reviews. 26 (4): 257–68. doi:10.1053/ctrv.2000.0170. PMID 10913381.

Thiotepa information

and 27 Related for: Thiotepa information

Thiotepa

Intrathecal administration

IARC group 1 Carcinogens

List of antineoplastic agents

Tretinoin

Methotrexate

Chemotherapy

Lifileucel

Hydroxycarbamide

Celecoxib

FOLFIRI

Paclitaxel

Abemaciclib

Vincristine

Antimetabolite

List of cytochrome P450 modulators

Doxorubicin

National Cancer Institute

Mercaptopurine

Cancer immunotherapy

Carboplatin

Venetoclax

Talazoparib

Nelarabine

Nocodazole

Fluorouracil

Etoposide